AAPL   278.29 (-4.91%)
FB   192.36 (-2.45%)
MSFT   161.34 (-5.19%)
GOOGL   1,337.71 (-3.79%)
AMZN   1,914.97 (-3.26%)
NVDA   259.84 (-2.92%)
BABA   206.15 (-1.24%)
MU   51.86 (-0.97%)
GE   10.67 (-2.56%)
TSLA   684.70 (-12.08%)
AMD   44.76 (-5.75%)
T   36.22 (-2.37%)
ACB   1.46 (-3.32%)
NFLX   378.55 (-0.18%)
BAC   29.65 (-3.20%)
DIS   119.92 (-2.79%)
GILD   72.83 (-2.50%)
AAPL   278.29 (-4.91%)
FB   192.36 (-2.45%)
MSFT   161.34 (-5.19%)
GOOGL   1,337.71 (-3.79%)
AMZN   1,914.97 (-3.26%)
NVDA   259.84 (-2.92%)
BABA   206.15 (-1.24%)
MU   51.86 (-0.97%)
GE   10.67 (-2.56%)
TSLA   684.70 (-12.08%)
AMD   44.76 (-5.75%)
T   36.22 (-2.37%)
ACB   1.46 (-3.32%)
NFLX   378.55 (-0.18%)
BAC   29.65 (-3.20%)
DIS   119.92 (-2.79%)
GILD   72.83 (-2.50%)
AAPL   278.29 (-4.91%)
FB   192.36 (-2.45%)
MSFT   161.34 (-5.19%)
GOOGL   1,337.71 (-3.79%)
AMZN   1,914.97 (-3.26%)
NVDA   259.84 (-2.92%)
BABA   206.15 (-1.24%)
MU   51.86 (-0.97%)
GE   10.67 (-2.56%)
TSLA   684.70 (-12.08%)
AMD   44.76 (-5.75%)
T   36.22 (-2.37%)
ACB   1.46 (-3.32%)
NFLX   378.55 (-0.18%)
BAC   29.65 (-3.20%)
DIS   119.92 (-2.79%)
GILD   72.83 (-2.50%)
AAPL   278.29 (-4.91%)
FB   192.36 (-2.45%)
MSFT   161.34 (-5.19%)
GOOGL   1,337.71 (-3.79%)
AMZN   1,914.97 (-3.26%)
NVDA   259.84 (-2.92%)
BABA   206.15 (-1.24%)
MU   51.86 (-0.97%)
GE   10.67 (-2.56%)
TSLA   684.70 (-12.08%)
AMD   44.76 (-5.75%)
T   36.22 (-2.37%)
ACB   1.46 (-3.32%)
NFLX   378.55 (-0.18%)
BAC   29.65 (-3.20%)
DIS   119.92 (-2.79%)
GILD   72.83 (-2.50%)
Log in

NASDAQ:BTAI - BioXcel Therapeutics Stock Price, Forecast & News

$33.44
+0.96 (+2.96 %)
(As of 02/27/2020 02:58 PM ET)
Today's Range
$29.46
Now: $33.44
$35.66
50-Day Range
$12.26
MA: $22.08
$41.14
52-Week Range
$3.76
Now: $33.44
$43.63
Volume737,147 shs
Average Volume885,486 shs
Market Capitalization$604.93 million
P/E RatioN/A
Dividend YieldN/A
Beta3.73
BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BTAI
CUSIPN/A
Phone475-238-6837

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.49 per share

Profitability

Net Income$-19,270,000.00

Miscellaneous

Employees18
Market Cap$604.93 million
Next Earnings Date3/5/2020 (Estimated)
OptionableNot Optionable

Receive BTAI News and Ratings via Email

Sign-up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter.


BioXcel Therapeutics (NASDAQ:BTAI) Frequently Asked Questions

What is BioXcel Therapeutics' stock symbol?

BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI."

How were BioXcel Therapeutics' earnings last quarter?

BioXcel Therapeutics Inc (NASDAQ:BTAI) announced its quarterly earnings data on Thursday, November, 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.02. View BioXcel Therapeutics' Earnings History.

When is BioXcel Therapeutics' next earnings date?

BioXcel Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for BioXcel Therapeutics.

What price target have analysts set for BTAI?

4 brokerages have issued 1-year price targets for BioXcel Therapeutics' shares. Their forecasts range from $24.00 to $30.00. On average, they anticipate BioXcel Therapeutics' share price to reach $26.75 in the next twelve months. This suggests that the stock has a possible downside of 20.0%. View Analyst Price Targets for BioXcel Therapeutics.

What is the consensus analysts' recommendation for BioXcel Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioXcel Therapeutics.

Has BioXcel Therapeutics been receiving favorable news coverage?

News headlines about BTAI stock have trended very negative recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BioXcel Therapeutics earned a news sentiment score of -3.7 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for BioXcel Therapeutics.

Are investors shorting BioXcel Therapeutics?

BioXcel Therapeutics saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 457,000 shares, a drop of 23.2% from the January 15th total of 595,200 shares. Based on an average daily volume of 233,400 shares, the days-to-cover ratio is currently 2.0 days. Approximately 5.6% of the company's shares are short sold. View BioXcel Therapeutics' Current Options Chain.

Who are some of BioXcel Therapeutics' key competitors?

What other stocks do shareholders of BioXcel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include Alibaba Group (BABA), Tesla (TSLA), NVIDIA (NVDA), Crispr Therapeutics (CRSP), Canopy Growth (CGC), Micron Technology (MU), Sangamo Therapeutics (SGMO), IQIYI (IQ), Sorrento Therapeutics (SRNE) and TherapeuticsMD (TXMD).

Who are BioXcel Therapeutics' key executives?

BioXcel Therapeutics' management team includes the folowing people:
  • Dr. Vimal D. Mehta Ph.D., Founder, CEO, Pres, Sec. & Director (Age 58)
  • Dr. Frank D. Yocca Ph.D., Chief Scientific Officer (Age 63)
  • Dr. Vincent J. O'Neill M.D., B.Sc., M.R.C.P., Sr. VP & Chief Medical Officer (Age 50)
  • Mr. Richard I. Steinhart MBA, Chief Financial Officer (Age 62)
  • Mr. Chids Mahadevan, VP of Fin. & Chief Accounting Officer (Age 47)

When did BioXcel Therapeutics IPO?

(BTAI) raised $60 million in an IPO on Thursday, March 8th 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Who are BioXcel Therapeutics' major shareholders?

BioXcel Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Artemis Investment Management LLP (5.95%), Point72 Asset Management L.P. (1.41%), Ikarian Capital LLC (0.88%), State Street Corp (0.55%), UBS Group AG (0.52%) and Geode Capital Management LLC (0.44%). Company insiders that own BioXcel Therapeutics stock include Frank Yocca, Peter Mueller, Richard I Steinhart and Vimal Mehta. View Institutional Ownership Trends for BioXcel Therapeutics.

Which major investors are selling BioXcel Therapeutics stock?

BTAI stock was sold by a variety of institutional investors in the last quarter, including Artemis Investment Management LLP, Renaissance Technologies LLC and Bank of America Corp DE. View Insider Buying and Selling for BioXcel Therapeutics.

Which major investors are buying BioXcel Therapeutics stock?

BTAI stock was acquired by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Banco Bilbao Vizcaya Argentaria S.A., Point72 Asset Management L.P., Oxford Asset Management LLP, Geode Capital Management LLC, State Street Corp, Creative Planning and UBS Group AG. Company insiders that have bought BioXcel Therapeutics stock in the last two years include Frank Yocca, Peter Mueller, Richard I Steinhart and Vimal Mehta. View Insider Buying and Selling for BioXcel Therapeutics.

How do I buy shares of BioXcel Therapeutics?

Shares of BTAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BioXcel Therapeutics' stock price today?

One share of BTAI stock can currently be purchased for approximately $33.44.

How big of a company is BioXcel Therapeutics?

BioXcel Therapeutics has a market capitalization of $604.93 million. The company earns $-19,270,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis. BioXcel Therapeutics employs 18 workers across the globe.View Additional Information About BioXcel Therapeutics.

What is BioXcel Therapeutics' official website?

The official website for BioXcel Therapeutics is http://www.bioxceltherapeutics.com/.

How can I contact BioXcel Therapeutics?

BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The company can be reached via phone at 475-238-6837 or via email at [email protected]thgroup.com.


MarketBeat Community Rating for BioXcel Therapeutics (NASDAQ BTAI)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  156 (Vote Outperform)
Underperform Votes:  160 (Vote Underperform)
Total Votes:  316
MarketBeat's community ratings are surveys of what our community members think about BioXcel Therapeutics and other stocks. Vote "Outperform" if you believe BTAI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTAI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel